Literature DB >> 32352155

Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.

Robson da Costa1, Giselle F Passos1, Nara L M Quintão2, Elizabeth S Fernandes3,4, João Raphael L C B Maia1, Maria Martha Campos5, João B Calixto6.   

Abstract

Taxane-derived drugs are antineoplastic agents used for the treatment of highly common malignancies. Paclitaxel and docetaxel are the most commonly used taxanes; however, other drugs and formulations have been used, such as cabazitaxel and nab-paclitaxel. Taxane treatment is associated with neurotoxicity, a well-known and relevant side effect, very prevalent amongst patients undergoing chemotherapy. Painful peripheral neuropathy is the most dose-limiting side effect of taxanes, affecting up to 97% of paclitaxel-treated patients. Central neurotoxicity is an emerging side effect of taxanes and it is characterized by cognitive impairment and encephalopathy. Besides impairing compliance to chemotherapy treatment, taxane-induced neurotoxicity (TIN) can adversely affect the patient's life quality on a long-term basis. Despite the clinical relevance, not many reviews have comprehensively addressed taxane-induced neurotoxicity when they are used therapeutically. This article provides an up-to-date review on the pathophysiology of TIN and the novel potential therapies to prevent or treat this side effect.
© 2020 The British Pharmacological Society.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32352155      PMCID： PMC7312267          DOI： 10.1111/bph.15086

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  158 in total

1.  Cinobufacini protects against paclitaxel-induced peripheral neuropathic pain and suppresses TRPV1 up-regulation and spinal astrocyte activation in rats.

Authors:  Xiyuan Ba; Jiali Wang; Shiyang Zhou; Xinxin Luo; Yun Peng; Shimin Yang; Yue Hao; Guangyi Jin
Journal:  Biomed Pharmacother       Date:  2018-09-12       Impact factor: 6.529

2.  Rolipram improves cognition, reduces anxiety- and despair-like behaviors and impacts hippocampal neuroplasticity after transient global cerebral ischemia.

Authors:  Lígia Mendes Soares; Jochen De Vry; Harry W M Steinbusch; Humberto Milani; Jos Prickaerts; Rúbia M Weffort de Oliveira
Journal:  Neuroscience       Date:  2016-04-04       Impact factor: 3.590

3.  Ataxia following docetaxel infusion.

Authors:  L S Hofstra; W T van der Graaf; E G de Vries; H Haaxma-Reiche; P H Willemse
Journal:  Ann Oncol       Date:  1997-08       Impact factor: 32.976

4.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Authors:  Stephan Fellner; Björn Bauer; David S Miller; Martina Schaffrik; Martina Fankhänel; Thilo Spruss; Günther Bernhardt; Claudia Graeff; Lothar Färber; Harald Gschaidmeier; Armin Buschauer; Gert Fricker
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

5.  Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.

Authors:  Anne Gangloff; Wei-Ann Hsueh; Amanda L Kesner; Dale O Kiesewetter; Betty S Pio; Mark D Pegram; Malgorzata Beryt; Allison Townsend; Johannes Czernin; Michael E Phelps; Daniel H S Silverman
Journal:  J Nucl Med       Date:  2005-11       Impact factor: 10.057

6.  Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3.

Authors:  Ravi D Rao; Patrick J Flynn; Jeff A Sloan; Gilbert Y Wong; Paul Novotny; David B Johnson; Howard M Gross; Samer I Renno; Mohammed Nashawaty; Charles L Loprinzi
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

7.  Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies.

Authors:  Sangsu Bang; Jiho Yoo; Xingrui Gong; Di Liu; Qingjian Han; Xin Luo; Wonseok Chang; Gang Chen; Sang-Taek Im; Yong Ho Kim; Judith A Strong; Ma-Zhong Zhang; Jun-Ming Zhang; Seok-Yong Lee; Ru-Rong Ji
Journal:  Neurosci Bull       Date:  2018-01-15       Impact factor: 5.203

8.  Taxanes for adjuvant treatment of early breast cancer.

Authors:  Melina L Willson; Lucinda Burke; Thomas Ferguson; Davina Ghersi; Anna K Nowak; Nicholas Wilcken
Journal:  Cochrane Database Syst Rev       Date:  2019-09-02

9.  Sodium channel Nav1.7 expression is upregulated in the dorsal root ganglia in a rat model of paclitaxel-induced peripheral neuropathy.

Authors:  Zhongyuan Xia; Yun Xiao; Yang Wu; Bo Zhao
Journal:  Springerplus       Date:  2016-10-06

10.  CXCR1/2 pathways in paclitaxel-induced neuropathic pain.

Authors:  Laura Brandolini; Elisabetta Benedetti; Pier Adelchi Ruffini; Roberto Russo; Loredana Cristiano; Andrea Antonosante; Michele d'Angelo; Vanessa Castelli; Antonio Giordano; Marcello Allegretti; Annamaria Cimini
Journal:  Oncotarget       Date:  2017-04-04
View more
  20 in total

Review 1.  Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.

Authors:  Robson da Costa; Giselle F Passos; Nara L M Quintão; Elizabeth S Fernandes; João Raphael L C B Maia; Maria Martha Campos; João B Calixto
Journal:  Br J Pharmacol       Date:  2020-06-03       Impact factor: 8.739

Review 2.  Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.

Authors:  Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann
Journal:  Drug Saf       Date:  2022-05-23       Impact factor: 5.606

3.  Impact of taxane-based chemotherapy among older women with breast cancer on cognition and quality of life: a longitudinal pooled analysis.

Authors:  Brent J Small; Marie Lange; Jeanne Mandelblatt; Florence Joly; Wanting Zhai; Jaeil Ahn; Tim A Ahles; Judith E Carroll; Harvey J Cohen; Deena Graham; Martine Extermann; Natacha Heutte; Heather S L Jim; Brenna C McDonald; Sunita K Patel; James C Root; Andrew J Saykin; Kathleen Van Dyk; Xingtao Zhou
Journal:  Breast Cancer Res Treat       Date:  2021-11-24       Impact factor: 4.872

4.  Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO.

Authors:  Matthias Zaiss; Jens Uhlig; Mark-Oliver Zahn; Thomas Decker; Helmar C Lehmann; Johanna Harde; Cathrin Hogrefe; Corinne Vannier; Norbert Marschner
Journal:  Oncol Res Treat       Date:  2021-09-08       Impact factor: 2.825

5.  Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.

Authors:  Alberto Guijosa; Ana Freyria; Jose Rodrigo Espinosa-Fernandez; Francisco J Estrada-Mena; Ana Sofía Armenta-Quiroga; Maria Fernanda Ortega-Treviño; Rodrigo Catalán; Bani Antonio-Aguirre; Cynthia Villarreal-Garza; Andric C Perez-Ortiz
Journal:  Clin Transl Sci       Date:  2022-08-17       Impact factor: 4.438

6.  7-Chloro-4-(Phenylselanyl) Quinoline Is a Novel Multitarget Therapy to Combat Peripheral Neuropathy and Comorbidities Induced by Paclitaxel in Mice.

Authors:  Jaini J Paltian; Angélica S Dos Reis; Amanda W S Martins; Eduardo B Blödorn; Eduardo N Dellagostin; Liane K Soares; Ricardo F Schumacher; Vinícius F Campos; Diego Alves; Cristiane Luchese; Ethel Antunes Wilhelm
Journal:  Mol Neurobiol       Date:  2022-08-15       Impact factor: 5.682

7.  Update on Toxic Neuropathies.

Authors:  Jannik Peters; Nathan P Staff
Journal:  Curr Treat Options Neurol       Date:  2022-04-06       Impact factor: 3.972

8.  Incidence density and factors associated with peripheral neuropathy among women with breast cancer during taxane-based chemotherapy.

Authors:  Nida Rattanakrong; Akkradate Siriphorn; Sujitra Boonyong
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

9.  Transcriptome profiling of long noncoding RNAs and mRNAs in spinal cord of a rat model of paclitaxel-induced peripheral neuropathy identifies potential mechanisms mediating neuroinflammation and pain.

Authors:  Yuanyuan Li; Chengyu Yin; Boyu Liu; Huimin Nie; Jie Wang; Danyi Zeng; Ruixiang Chen; Xiaofen He; Junfan Fang; Junying Du; Yi Liang; Yongliang Jiang; Jianqiao Fang; Boyi Liu
Journal:  J Neuroinflammation       Date:  2021-02-18       Impact factor: 8.322

10.  Pharmacological rescue of cognitive function in a mouse model of chemobrain.

Authors:  Lien D Nguyen; Tom T Fischer; Barbara E Ehrlich
Journal:  Mol Neurodegener       Date:  2021-06-26       Impact factor: 14.195
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.